page-title

The Risk of Misdiagnosis – Is It Lewy Body Disease or Alzheimer’s?

According to Howard Hurtig, M.D., Chair, Department of Neurology, Pennsylvania Hospital, “While the
symptoms of Lewy Body Disease (LBD) may be similar to Alzheimer’s and Parkinson’s disease, the treatment
strategy is more challenging because fewer medications can be used safely. I cannot overemphasize the need
to avoid medications that can worsen the symptoms of LBD. Every patient with this disease and their caregivers
should be familiar with the list of acceptable and forbidden drugs.”

Lewy body dementia is the most misdiagnosed cause of progressive dementia

When dealing with this vulnerable patient group, particular attention must be paid when recruiting and
selecting subjects for clinical trials. It is essential to be able to detect the difference between Alzheimer’s
disease, Lewy Body Disease as well as other dementias that have similar profiles and symptoms.
ADM Diagnostics has developed a proprietary brain imaging software platform that uses pattern recognition
to differentiate between Alzheimer’s, LBD and other dementias at a extraordinary high rate. The software uses
machine learning and reference data of over 1,400 subjects and 6,000 images of Normals, Alzheimer’s,
Frontotemporal Dementia (FTD), Lewy Body Disease and Semantic Dementia. According to the Lewy Body
Dementia Association (LBDA), accurate and early diagnosis is critical because people with LBD typically have
sensitivities to medication, and many drugs prescribed for Alzheimer’s can be very harmful to those with LBD.

Safety concerns are even greater when dealing with an investigational drug during a clinical trial.
Using PET imaging and this highly advanced software, ADM Diagnostics has been able to accurately diagnosis
and classify patients into the most appropriate category. ADM Diagnostics is using this program to help
pharmaceutical and biopharmaceutical companies, contract research organizations and academic labs enroll
subjects for clinical trials that are the most appropriate candidates for the investigational drug being tested
increasing the ability to detect drug efficacy while reducing the risk to the patients in the study.

To learn more about ADM Diagnostics and our ability to improve subject selection and stratification, please
contact Midori Yokoyama (myokoyama@admdx.com) or Craig Pennington (cpennington@admdx.com).